Your browser doesn't support javascript.
loading
Key considerations in the preclinical development of biosimilars.
Bui, Lynne A; Hurst, Susan; Finch, Gregory L; Ingram, Beverly; Jacobs, Ira A; Kirchhoff, Carol F; Ng, Chee-Keng; Ryan, Anne M.
Afiliação
  • Bui LA; Global Cancer Research Institute, Inc. (GCRI) for Personalized Oncology, San Jose, CA 95124, USA. Electronic address: lbui@gcrioncology.com.
  • Hurst S; Development Strategies Group in the PDM (Pharmacokinetics, Dynamics, and Metabolism) Department, Pfizer Inc, Groton, CT 06340, USA.
  • Finch GL; Drug Safety Research and Development, Pfizer Inc, Groton, CT 06340, USA.
  • Ingram B; Pfizer Inc, Andover, MA 01810, USA.
  • Jacobs IA; Pfizer Emerging Markets/Established Products Medicines Development Group, Pfizer Inc, New York, NY 10017, USA.
  • Kirchhoff CF; Global Technology Services - BioManufacturing Sciences Group, Pfizer Inc, Chesterfield, MO 63017, USA.
  • Ng CK; Pfizer Inc, Andover, MA 01810, USA.
  • Ryan AM; Drug Safety Research and Development, Pfizer Inc, Groton, CT 06340, USA.
Drug Discov Today ; 20 Suppl 1: 3-15, 2015 May.
Article em En | MEDLINE | ID: mdl-25912284
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Indústria Farmacêutica / Avaliação Pré-Clínica de Medicamentos / Medicamentos Biossimilares Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: Drug Discov Today Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Indústria Farmacêutica / Avaliação Pré-Clínica de Medicamentos / Medicamentos Biossimilares Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: Drug Discov Today Ano de publicação: 2015 Tipo de documento: Article